Financial reports
10-Q
2024 Q1
Quarterly report
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
Current reports
8-K
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
13 Jun 24
8-K
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
9 May 24
8-K
Other Events
28 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
21 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
9 Nov 23
8-K
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
17 Oct 23
8-K
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
16 Oct 23
8-K
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
10 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
25 Mar 24
S-8
Registration of securities for employees
3 Jan 24
S-3/A
Shelf registration (amended)
24 Apr 23
S-3
Shelf registration
17 Mar 23
S-8
Registration of securities for employees
9 Jan 23
424B5
Prospectus supplement for primary offering
26 Apr 22
424B5
Prospectus supplement for primary offering
25 Apr 22
S-8
Registration of securities for employees
17 Mar 22
424B5
Prospectus supplement for primary offering
3 Sep 21
S-3
Shelf registration
12 Aug 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
Other
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
UPLOAD
Letter from SEC
21 Mar 23
EFFECT
Notice of effectiveness
3 Sep 21
CORRESP
Correspondence with SEC
31 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
EFFECT
Notice of effectiveness
10 Jul 20
CERT
Certification of approval for exchange listing
9 Jul 20
CORRESP
Correspondence with SEC
8 Jul 20
UPLOAD
Letter from SEC
8 Jul 20